FGFR 1-3 Inhibitor Pemigatinib | Hackensack Meridian Health   

Hackensack University Medical Center Investigates Safety and Efficacy of Promising Precision Therapy in FIGHT-101 Trial

Marks First In-Human Study of FGFR 1-3 Inhibitor Pemigatinib


Hackensack University Medical Center researchers helped vet the safety and efficacy of pemigatinib, a new precision therapy. The key findings, published in the Annals of Oncology, include:

  • Pemigatinib was found safe and demonstrated pharmacodynamic and clinical activity, with responses seen across tumors and driven by FGFR fusions/rearrangements and mutations.
  • The treatment was active across a broad spectrum of tumors, most commonly in cholangiocarcinoma.
  • Pemigatinib may potentially offer benefits in other cancers with FGFR rearrangements and/or mutations.

The phase I/II FIGHT-101 study evaluated safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of pemigatinib, a potent and selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor, as monotherapy or in combination therapy, for refractory advanced malignancies, with and without fibroblast growth factor (FGF) and receptor (FGFR) gene alterations.

The study outcomes supported those of FIGHT-202 that led to pemigatinib approval for advanced FGFR2-rearranged cholangiocarcinoma. The Phase I/II study’s results led to a registrational study in cholangiocarcinoma and phase II/III trials in multiple tumor types validating the benefit of precision therapy.

Learn more about innovative cancer treatments at Hackensack University Medical Center.

Best Regional Hospitals
We use cookies to improve your experience. Please read our Privacy Policy or click Accept.